Trials / Completed
CompletedNCT00584584
An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever
A Proof of Concept Study of the Effects of QAX576 (an Interleukin-13 Monoclonal Antibody) on Allergic Inflammation Following Out of Allergy Season Repeated Nasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis Sensitive to Timothy Grass Pollen
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAX576 | |
| DRUG | Placebo |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-08-01
- First posted
- 2008-01-02
- Last updated
- 2017-02-24
Locations
2 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00584584. Inclusion in this directory is not an endorsement.